251 related articles for article (PubMed ID: 25789957)
21. A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI).
Ji F; Liang Y; Fu SJ; Guo ZY; Shu M; Shen SL; Li SQ; Peng BG; Liang LJ; Hua YP
BMC Cancer; 2016 Feb; 16():137. PubMed ID: 26907597
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of preoperative neutrophil-to-lymphocyte ratio in papillary renal cell carcinoma patients after receiving curative surgery based on a retrospective cohort.
Zhang Z; Yu Y; Zheng J; Zhang M; Niu H
BMC Urol; 2021 Mar; 21(1):43. PubMed ID: 33752642
[TBL] [Abstract][Full Text] [Related]
23. Blood neutrophil-lymphocyte ratio predicts survival after hepatectomy for hepatocellular carcinoma: A propensity score-based analysis.
Yang HJ; Guo Z; Yang YT; Jiang JH; Qi YP; Li JJ; Li LQ; Xiang BD
World J Gastroenterol; 2016 Jun; 22(21):5088-95. PubMed ID: 27275101
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.
Harimoto N; Shirabe K; Nakagawara H; Toshima T; Yamashita Y; Ikegami T; Yoshizumi T; Soejima Y; Ikeda T; Maehara Y
Transplantation; 2013 Dec; 96(11):1008-12. PubMed ID: 24113512
[TBL] [Abstract][Full Text] [Related]
25. Underlying liver disease and advanced stage liver cancer are associated with elevated neutrophil-lymphocyte ratio.
Wong L; Bozhilov K; Hernandez B; Kwee S; Chan O; Ellis L; LeMarchand L
Clin Mol Hepatol; 2019 Sep; 25(3):305-316. PubMed ID: 31001964
[TBL] [Abstract][Full Text] [Related]
26. The combination of plasma fibrinogen and neutrophil lymphocyte ratio (F-NLR) is a predictive factor in patients with resectable non small cell lung cancer.
Wang H; Zhao J; Zhang M; Han L; Wang M; Xingde L
J Cell Physiol; 2018 May; 233(5):4216-4224. PubMed ID: 29057536
[TBL] [Abstract][Full Text] [Related]
27. Neutrophil-lymphocyte Ratio Plus Prognostic Nutritional Index Predicts the Outcomes of Patients with Unresectable Hepatocellular Carcinoma After Transarterial Chemoembolization.
Liu C; Li L; Lu WS; Du H; Yan LN; Yang JY; Wen TF; Zeng GJ; Jiang L; Yang J
Sci Rep; 2017 Oct; 7(1):13873. PubMed ID: 29066730
[TBL] [Abstract][Full Text] [Related]
28. [Correlation between postoperative neutrophil to lymphocyte ratio and recurrence and prognosis of hepatocellular carcinoma after radical liver resection].
Wu XL; Bi XY; Li ZY; Zhao H; Zhao JJ; Zhou JG; Huang Z; Zhang YF; Cai JQ
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):365-371. PubMed ID: 29860764
[No Abstract] [Full Text] [Related]
29. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
Lee S; Rhim H; Kim YS; Kang TW; Song KD
Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of inflammatory and nutritional markers for hepatocellular carcinoma.
Xu Y; Yuan X; Zhang X; Hu W; Wang Z; Yao L; Zong L
Medicine (Baltimore); 2021 Jun; 100(25):e26506. PubMed ID: 34160470
[TBL] [Abstract][Full Text] [Related]
31. The lymphocyte-to-monocyte ratio is a superior predictor of overall survival compared to established biomarkers in HCC patients undergoing liver resection.
Yang YT; Jiang JH; Yang HJ; Wu ZJ; Xiao ZM; Xiang BD
Sci Rep; 2018 Feb; 8(1):2535. PubMed ID: 29416061
[TBL] [Abstract][Full Text] [Related]
32. A novel prognostic score model based on combining systemic and hepatic inflammation markers in the prognosis of HBV-associated hepatocellular carcinoma patients.
Zhang T; Liu Z; Zhao X; Mao Z; Bai L
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):2246-2255. PubMed ID: 31169437
[No Abstract] [Full Text] [Related]
33. Prognostic effect of preoperative neutrophil-lymphocyte ratio is related with tumor necrosis and tumor-infiltrating lymphocytes in hepatocellular carcinoma.
Ha SY; Choi S; Park S; Kim JM; Choi GS; Joh JW; Park CK
Virchows Arch; 2020 Dec; 477(6):807-816. PubMed ID: 32483662
[TBL] [Abstract][Full Text] [Related]
34. Neutrophil-to-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma: a Western perspective.
Sullivan KM; Groeschl RT; Turaga KK; Tsai S; Christians KK; White SB; Rilling WS; Pilgrim CH; Gamblin TC
J Surg Oncol; 2014 Feb; 109(2):95-7. PubMed ID: 24122764
[TBL] [Abstract][Full Text] [Related]
35. Combined Hangzhou criteria with neutrophil-lymphocyte ratio is superior to other criteria in selecting liver transplantation candidates with HBV-related hepatocellular carcinoma.
Xiao GQ; Yang JY; Yan LN
Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):588-95. PubMed ID: 26663006
[TBL] [Abstract][Full Text] [Related]
36. The Severity of Liver Fibrosis Influences the Prognostic Value of Inflammation-Based Scores in Hepatitis B-Associated Hepatocellular Carcinoma.
Wang Q; Blank S; Fiel MI; Kadri H; Luan W; Warren L; Zhu A; Deaderick PA; Sarpel U; Labow DM; Hiotis SP
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1125-32. PubMed ID: 26159441
[TBL] [Abstract][Full Text] [Related]
37. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.
Gomaa AI; Al-Khatib A; Abdel-Razek W; Hashim MS; Waked I
World J Gastroenterol; 2015 May; 21(18):5654-62. PubMed ID: 25987792
[TBL] [Abstract][Full Text] [Related]
38. Validation of inflammation-based prognostic models in patients with hepatitis B-associated hepatocellular carcinoma: a retrospective observational study.
Pang Q; Zhou L; Qu K; Cui RX; Jin H; Liu HC
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):60-70. PubMed ID: 29189392
[TBL] [Abstract][Full Text] [Related]
39. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
[TBL] [Abstract][Full Text] [Related]
40. Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma.
Li X; Chen ZH; Ma XK; Chen J; Wu DH; Lin Q; Dong M; Wei L; Wang TT; Ruan DY; Lin ZX; Xing YF; Deng Y; Wu XY; Wen JY
Tumour Biol; 2014 Nov; 35(11):11057-63. PubMed ID: 25095975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
